Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are of European American background, have a DNA sample available, and have been identified as either a "case" or "control" participant.
- You are of African American background, have a DNA sample available, and have been identified as either a "case" or "control" participant.
- You are African American and developed moderate to severe nerve damage (grade 2-4) in your hands or feet during treatment with the chemotherapy drug paclitaxel, OR you are European American and developed severe nerve damage (grade 3-4) during paclitaxel treatment.
- You completed a full course of paclitaxel treatment without developing any nerve damage in your hands or feet (confirm with trial site).
Who may not be able to join:
- There are no specific exclusion criteria listed in the official trial information (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identification of rare coding variants of large effect that predict the risk of peripheral neuropathy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.